Abstract
Streptokinase (SK) is a therapeutically important thrombolytic agent. Cardiovascular disease is the first cause of adult death worldwide. In Egypt about 13% of the population die every year due to ischemic heart disease. In spite of this fact, there is no local production of cardiovascular therapeutics. We reported for the first time the expression of a recombinant SK from a local Streptococcus strain. When produced on industrial scale this r-SK may substantially contribute to reducing the costs of thrombolytic therapy in developing countries. In this study, a highly purified r-SK from Streptococcus sp. isolated from Egyptian pharyngitis patients was obtained. The isolated strain was partially identified using 16S rDNA sequencing and namedStreptococcus sp. SalMarEg. It was found to be phylogenetically related toStreptococcus pyogenes. Analysis of the obtained sequence showed high similarity with other SK genes. The protein expression in a prokaryotic system obtained a 47-kDa SK protein that could be purified using a single-step his-tagged affinity purification chromatography, with nearly 80% recovery. The clot lytic activities of both recombinant and commercial SK were similar, thus giving the basis to scale up this SK product in order to evaluate the possibilities of its commercialization in local and/or regional markets. Key words: Streptokinase, Streptococcus SalMarEg, thrombolytic agent,heterologous expression.
Highlights
Cardiovascular disease is one of the leading causes of death worldwide
According to World Health Organization (WHO) about 13% of Egyptian population die every year due to ischemic heart disease, which is considered the first cause of adult death in Egypt
It is known that the administration of a thrombolytic agent within six hours of the chest pain onset would reduce the risk of death by 40%
Summary
Cardiovascular disease is one of the leading causes of death worldwide. According to World Health Organization (WHO) about 13% of Egyptian population die every year due to ischemic heart disease, which is considered the first cause of adult death in Egypt. Intravenous thrombolysis is the standard therapeutic approach for patients with acute myocardial infarction (Murray et al, 2010). Streptokinase (SK) is a life-saving clot-dissolving drug routinely prescribed universally in the management of Abbreviations: SK, Streptokinase; r, recombinant. Heart attack (Banerjee et al, 2004). It is the leading fibrinolytic agent in the treatment of thromboembolic conditions (Boersma et al, 2003). It is known that the administration of a thrombolytic agent within six hours of the chest pain onset would reduce the risk of death by 40%
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
